MAHA Enables Edit‑Market Normalization

If courts uphold the MAHA argument to permit advanced embryo editing, it will quickly convert speculative bioethical debates into a mass market: clinics, analytics firms, and insurers will standardize offerings for protective and enhancement edits, and third‑party vendors will monetize trait scoring and matchmaking. — Legalizing advanced germline edits would shift the policy question from 'should we?' to 'how do we regulate markets, access, and equity,' with implications for health law, inequality, and biosecurity.